In this perspective, we examined the present and future interface of AI & translational cancer research for @cp-cancercell.bsky.social - led by the stellar Dr. Josephine Yates! @danafarber.bsky.social @broadinstitute.org www.sciencedirect.com/science/arti...

Here's our latest - jointly with @rhaq1.bsky.social lab & co-lead by Drs. Schiantarelli, Benamar, Park et al - studying why some tumors stop responding to immunotherapy. This continues to be a tough puzzle to solve, but important for science & patients alike...

#SaveThePCC Some of you may have read about the situation regarding our new landlord wishing to add a new redevelopment break clause, with only 6 months notice to our lease. For now, we're simply asking you all to share & sign the petition below; you.38degrees.org.uk/p/princechar...

PARP inhibitor, olaparib, has transformed treatment for men whose #prostatecancer has DNA repair defects, but most cancers eventually become resistant. @seedgeorge.bsky.social at @icrlondon.bsky.social has uncovered genomic changes that predict how long men will respond.🧵 doi.org/10.1016/j.cc...

Delighted that a major project of my post-doctoral fellowship in the de Bono lab has been published. A really interesting story, featuring the likes of @icrlordlab.bsky.social @boragurel.bsky.social among many others at @icrlondon.bsky.social and elsewhere.

This weeks coffee club paper focuses on genomic changes linked to PARP inhibitor resistance ☕ The work was led by @prostatecanceruk.bsky.social's Travel Prize Fellow @seedgeorge.bsky.social from @icrlondon.bsky.social Congratulations to George and team 🥳 t.co/rC22HnAKIs #prostatecancer #research